Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A.
Manglaviti S, et al. Among authors: occhipinti m.
Clin Lung Cancer. 2022 Jan;23(1):e17-e28. doi: 10.1016/j.cllc.2021.06.013. Epub 2021 Jul 5.
Clin Lung Cancer. 2022.
PMID: 34334296
In UH group, programmed death-ligand 1 (PD-L1) <1%, 1-49%, 50% and unknown expression were reported in 27.8%, 22.8%, 31.7% and 17.7% patients respectively and ICI was the second/further-line in the majority of patients. After a median follow-up of 35.64 months (m), medi …
In UH group, programmed death-ligand 1 (PD-L1) <1%, 1-49%, 50% and unknown expression were reported in 27.8%, 22.8%, 31.7% and 17.7% pati …